Prognostic role of caveolin in breast cancer: a meta-analysis.

[1]  A. El-Gendi,et al.  Stromal Caveolin-1 Expression in Breast Carcinoma. Correlation with Early Tumor Recurrence and Clinical Outcome , 2012, Pathology & Oncology Research.

[2]  F. Sotgia,et al.  Caveolin-1 and cancer metabolism in the tumor microenvironment: markers, models, and mechanisms. , 2012, Annual review of pathology.

[3]  H. Lane,et al.  Significant association of caveolin-1 (CAV1) genotypes with breast cancer in Taiwan. , 2011, Anticancer research.

[4]  T. Inamoto,et al.  Prognostic significance of tumor/stromal caveolin‐1 expression in breast cancer patients , 2011, Cancer science.

[5]  Seho Park,et al.  The impact of caveolin protein expression in tumor stroma on prognosis of breast cancer , 2011, Tumor Biology.

[6]  F. Sotgia,et al.  Loss of stromal caveolin-1 expression predicts poor clinical outcome in triple negative and basal-like breast cancers , 2010, Cancer biology & therapy.

[7]  T. Ueno,et al.  Is dysfunction of caveolin-1 a link between systemic sclerosis and breast cancer, opening a window on both etiologies? , 2010, Archives of medical research.

[8]  N Harbeck,et al.  Triple-negative breast cancer--current status and future directions. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  H. Rui,et al.  Stromal caveolin-1 levels predict early DCIS progression to invasive breast cancer , 2009, Cancer biology & therapy.

[10]  F. Sotgia,et al.  An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. , 2009, The American journal of pathology.

[11]  F. Sotgia,et al.  Towards a new “stromal-based” classification system for human breast cancer prognosis and therapy , 2009, Cell cycle.

[12]  C. Restall,et al.  Stromal cell expression of caveolin-1 predicts outcome in breast cancer. , 2009, The American journal of pathology.

[13]  F. Sotgia,et al.  Using Caveolin-1 epithelial immunostaining patterns to stratify human breast cancer patients and to predict the Caveolin-1 (P132L) mutation , 2009, Cell cycle.

[14]  P. Bonnier,et al.  A signature predictive of disease outcome in breast carcinomas, identified by quantitative immunocytochemical assays , 2009, International journal of cancer.

[15]  S. Wiseman,et al.  Phosphorylated caveolin-1 regulates Rho/ROCK-dependent focal adhesion dynamics and tumor cell migration and invasion. , 2008, Cancer research.

[16]  A. Rosenberg,et al.  Human breast cancer-associated fibroblasts (CAFs) show caveolin-1 down-regulation and RB tumor suppressor functional inactivation: Implications for the response to hormonal therapy , 2008, Cancer biology & therapy.

[17]  I. Ellis,et al.  Caveolin 1 and Caveolin 2 are associated with breast cancer basal-like and triple-negative immunophenotype , 2008, British Journal of Cancer.

[18]  Robin L. Jones,et al.  Distribution and significance of caveolin 2 expression in normal breast and invasive breast cancer: an immunofluorescence and immunohistochemical analysis , 2008, Breast Cancer Research and Treatment.

[19]  H. Yamashiro,et al.  Update of evidence in chemotherapy for breast cancer , 2008, International Journal of Clinical Oncology.

[20]  C. Liedtke,et al.  Caveolin-1 expression in benign and malignant lesions of the breast , 2007, World journal of surgical oncology.

[21]  M. Sydes,et al.  Practical methods for incorporating summary time-to-event data into meta-analysis , 2007, Trials.

[22]  P. Bonnier,et al.  Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype. , 2007, Human pathology.

[23]  Robin L. Jones,et al.  Caveolin 1 Is Overexpressed and Amplified in a Subset of Basal-like and Metaplastic Breast Carcinomas: A Morphologic, Ultrastructural, Immunohistochemical, and In situ Hybridization Analysis , 2007, Clinical Cancer Research.

[24]  H. Rui,et al.  Stromal and epithelial caveolin-1 both confer a protective effect against mammary hyperplasia and tumorigenesis: Caveolin-1 antagonizes cyclin D1 function in mammary epithelial cells. , 2006, The American journal of pathology.

[25]  Robert A. Weinberg,et al.  Stromal Fibroblasts in Cancer: A Novel Tumor-Promoting Cell Type , 2006, Cell cycle.

[26]  Wan-Cai Yang,et al.  Caveolin-1 mutations in human breast cancer: functional association with estrogen receptor alpha-positive status. , 2006, The American journal of pathology.

[27]  J. Benítez,et al.  Caveolin-1 expression is associated with a basal-like phenotype in sporadic and hereditary breast cancer , 2006, Breast Cancer Research and Treatment.

[28]  F. Sotgia,et al.  Genetic ablation of caveolin-1 in mammary epithelial cells increases milk production and hyper-activates STAT5a signaling , 2006, Cancer biology & therapy.

[29]  S. Kim,et al.  Caveolin‐1 is down‐regulated and inversely correlated with HER2 and EGFR expression status in invasive ductal carcinoma of the breast , 2005, Histopathology.

[30]  H. Moses,et al.  Stromal fibroblasts in cancer initiation and progression , 2004, Nature.

[31]  K. Mimori,et al.  Clinical significance of Caveolin-1, Caveolin-2 and HER2/neu mRNA expression in human breast cancer , 2004, British Journal of Cancer.

[32]  M. Lisanti,et al.  The biology of caveolae: lessons from caveolin knockout mice and implications for human disease. , 2003, Molecular interventions.

[33]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[34]  R. Glazer,et al.  Transformation of mammary epithelial cells by 3-phosphoinositide- dependent protein kinase-1 activates beta-catenin and c-Myc, and down-regulates caveolin-1. , 2003, Cancer research.

[35]  Paula R Williamson,et al.  Aggregate data meta‐analysis with time‐to‐event outcomes , 2002, Statistics in medicine.

[36]  C. Isaacs,et al.  Prognostic Factors in Breast Cancer: Current and New Predictors of Metastasis , 2001, Journal of Mammary Gland Biology and Neoplasia.

[37]  C. Peschle,et al.  Expression of Caveolin-1 Is Required for the Transport of Caveolin-2 to the Plasma Membrane , 1999, The Journal of Biological Chemistry.

[38]  M. Parmar,et al.  Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. , 1998, Statistics in medicine.

[39]  M. Kattan,et al.  Elevated expression of caveolin is associated with prostate and breast cancer. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[40]  J. Cornfield,et al.  A method of estimating comparative rates from clinical data; applications to cancer of the lung, breast, and cervix. , 1951, Journal of the National Cancer Institute.

[41]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[42]  Giuseppe Perrone,et al.  Caveolin-1 expression in human breast lobular cancer progression , 2009, Modern Pathology.